Brad Fluegel Joins NeuroMetrix Board of Directors

NeuroMetrix Inc. has appointed Bradley M. Fluegel to its Board of Directors.

“We are pleased to welcome Brad to the NeuroMetrix Board of Directors,” said Shai N. Gozani, M.D., Ph.D., chairman and CEO. “His extensive strategic and operational experience in value-based care, medical technology, digital health and overall thought leadership in healthcare aligns well with the key elements of our growth strategy. “We look forward to working closely with Brad and leveraging his leadership and insights for the benefit of the Company.”
 
Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25-plus years, primarily in healthcare strategy and business development. Most recently, Fluegel was senior vice president, Chief Healthcare Commercial Market Development officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Prior to this role, he served as Walgreens’ Chief Strategy and Business Development officer. Fluegel is a senior advisor to Walgreens.
 
Previously, Fluegel was executive in residence at Health Evolution Partners. Earlier in his career, he was executive vice president, Chief Strategy and External Affairs officer at Wellpoint (now Elevance Health), senior vice president of National Accounts and vice president, Enterprise Strategy at Aetna, CEO for Reden & Anders (Optum Consulting) and principal at Tillinghast-Towers Perrin, a clinical, actuarial and management consulting practice serving the healthcare industry.
 
Fluegel currently serves on the Boards of Directors of Performant Financial Corporation, Premera Blue Cross, AdhereHealth and the Metropolitan Jewish Health System in New York City. Fluegel was also on the boards of Fitbit and Itamar Medical, both Nasdaq traded companies, until they were recently acquired.

Fluegel earned a master’s degree in public policy from Harvard University and a bachelor’s degree in business administration from the University of Washington. He is a lecturer in the Health Care Management Department at the Wharton School of the University of Pennsylvania.
 
“NeuroMetrix presents the exciting challenge of a commercial stage company with unique products that address large and important unmet needs in the areas of neurology and chronic pain,” said Fluegel. “I look forward to working with the NeuroMetrix team as the company grows and continues to positively impact the lives of individual patients and more broadly, population health.”
 
NeuroMetrix is on a mission to improve individual and population health through medical devices and technology solutions for neurological disorders and pain syndromes. The company has three commercial products. DPNCheck is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies, ADVANCE is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies, and Quell is a wearable neuromodulation technology indicated for treatment of fibromyalgia symptoms and chronic lower extremity pain.